The phase 1b trial’s primary endpoints are the occurrence of adverse events, including dose-limiting toxicities, and the ...

Bristol Myers Squibb didn’t want to choose between clinical expertise and financial know-how when selecting a new leader. | ...

BioNTech is buying fellow German mRNA vaccine developer CureVac in an all-stock transaction that values the acquired biotech ...

CSPC will use its artificial-intelligence-driven, dual-engine efficient drug discovery platform to analyze the binding ...

Wegovy maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early ...

After 25 years developing vaccines with French drugmaker Sanofi, Sanjay Gurunathan, M.D., has departed for GSK. Gurunathan ...

Once hailed as the future of immuno-oncology, it’s been a tough few months for any remaining fans of anti-TIGIT antibodies. | ...

Atraverse Medical has raised $29.4 million to fund its minimally invasive system for accessing the inner chambers of the ...

The offer is the result of a memorandum of understanding signed by both Astellas and Japanese think tank Mitsubishi Research ...

The Food and Drug Administration has gone all in on AI since Martin Makary, M.D., took over the agency, most recently ...

Novo Nordisk has planted another seed to fuel the blossoming of its obesity business, inking an $812 million deal with Deep ...

Medtronic has landed on a new brand for the planned spinout of its diabetes division, and it didn’t have to look very far. | ...